My first real chapter in clinical research was in project management and customer delivery, building electronic diaries on PalmPilots in the early 2000s. These were some of the first global eCOA deployments, back when “digital trials” mostly meant getting a device to turn on, capture data, and survive a FedEx shipment across the world.
From there, I joined Medidata, where I became a senior member of the solutions consulting team. We worked closely with commercial teams and clients as the industry began moving from point solutions toward unified eClinical platforms. Later, I joined the product team that helped build out Medidata’s eCOA and decentralized trial capabilities, which became the company’s fastest-growing solution area since EDC.
My first run inside pharma came at Bristol Myers Squibb during the COVID years, where I led the Clinical Innovation team within Clinical Operations. That role came with plenty of experiments, a few failures, and a lot of learning. But two major initiatives made it all the way from pilot to implementation: EHR-to-EDC and decentralized clinical trials.
After BMS, I moved to Medable as VP of Product Strategy, helping shape the company’s platform vision and long-term growth strategy. I also served as GM for eCOA, overseeing major product releases and working closely with clients to define the roadmap for new capabilities.
At Biofourmis, I again led product strategy as a VP, working closely with the executive team as we refined the clinical trials business, sharpened the go-to-market strategy, and ultimately supported the sale of the clinical trials division to ActiGraph in December 2024, now part of Signant Health.
In 2025, I moved into full-time consulting, working with pharma companies, technology vendors, startups, investors, and clinical research sites. That year gave me a broader view of the market and a much closer look at one trend I believe will reshape the next era of clinical development: research sites are starting to take control of their own technology stacks. Large and small sites are investing in their own eClinical infrastructure and asking why they should rebuild their workflows around a different sponsor-mandated system for every study. That movement — Bring Your Own Technology, or BYOT — is still early, but it is gaining momentum globally.
Across 20+ years, I’ve worked in operations, delivery, pre-sales, sales, product development, strategy, consulting, and executive leadership. I’ve seen the industry from the vendor side, the sponsor side, the startup side, and the advisory side.
And the honest answer is: there is still a lot more to do.